Kovo Completes Shares for Debt Transaction
Kovo Completes Shares for Debt Transaction
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Kovo Healthtech Corporation (TSXV: KOVO) ("Kovo" or the "Corporation") is pleased to announce that, further to its news release dated May 20, 2024, the TSX Venture Exchange (the "TSXV") has approved the Corporation's previously announced debt conversion transaction (the "Debt Conversion Transaction") and the Corporation settled outstanding debt in the aggregate amount CDN$2,257,229.56 owing to its largest secured creditor, Avonlea Ventures #2 Inc. ("AVI") by issuing 57,543,906 common shares in the capital of the Corporation ("Common Shares") at a deemed issue price per Common Share equal to $0.035 and 4,863,861 Common Shares at a deemed issue price per Common Share equal to $0.05. In aggregate, 62,407,767 Common Shares (the "Settlement Shares") were issued to AVI and are subject to a customary four month plus one day hold period.
溫哥華,不列顛哥倫比亞省--(新聞稿社 - 2024年7月24日) -Kovo Healthtech Corporation (TSXV: KOVO) (以下簡稱“Kovo”或“公司”)很高興地宣佈,根據2024年5月20日發佈的新聞稿,TSX Venture Exchange(以下簡稱“TSXV”)已覈准公司此前宣佈的債務轉換交易(以下簡稱“債務轉換交易”),並通過以$0.035發行57,543,906股公司(“普通股”)和以$0.05發行4,863,861股公司的價格償還其最大的有擔保債權人Avonlea Ventures#2 Inc.(“AVI”)所拖欠的總額爲CDN$2,257,229.56的欠款。總計發行了62,407,767股普通股(以下簡稱“和解股份”)給AVI,受到慣常的四個月加一天的凍結期的限制。
Upon the TSXV acceptance of the Debt Conversion Transaction: (i) the forbearance agreement dated February 27, 2024 between Kovo and AVI terminated and the Corporation is no longer subject to the default interest rate provided for in the senior loan and security agreement dated as of April 20, 2023 (the "Loan Agreement"); and (ii) the amendment and restatement of the Loan Agreement (the "Amended and Restated Loan Agreement") is deemed effective and, among other things, extends the maturity date of the remaining indebtedness owed to AVI (the "Remaining Indebtedness") to April 30, 2025 and provides AVI with the right to convert the Remaining Indebtedness into Common Shares (the "Additional Conversion Right") at a fixed price of CDN$0.05 per share (the "Loan Agreement Amendments", with the Debt Conversion Transaction and the Loan Agreement Amendments collectively, the "Transaction"). As a condition to obtaining the TSXV acceptance, the Corporation and AVI filed undertakings with the TSXV confirming that: (i) Kovo has not and will not make any adjustments to the outstanding equity incentive awards issued under the Corporation's equity incentive plan as a consequence of or in respect of the Transaction; and (ii) AVI shall not exercise its Additional Conversion Right unless, after such conversion, Kovo continues to meet the applicable Continued Listing Requirements in accordance with the policies of the TSXV.
在TSXV接受債務轉換交易後:(i) 2024年2月27日Kovo與AVI的自我剋制協議終止,公司不再受制於自2023年4月20日《貸款協議》中提供的違約利率;和(ii)貸款協議的修正和重籤(“修訂貸款協議”)被視爲生效,並且在其他事項中將應對其所欠AVI的尚未償還債務(“剩餘欠款”)的到期日延長至2025年4月30日,並向AVI提供在每股CDN$0.05的固定價格上將剩餘欠款轉換爲普通股的權利(“其他轉換權”)(“貸款協議修訂”,包括債務轉換交易和貸款協議修訂在內,均稱爲“交易”)。作爲獲得TSXV接受的條件,公司和AVI向TSXV提交承諾,確認:(i) Kovo未且不會由於交易而對公司的權益激勵計劃下已發行的未解決的股權激勵獎勵進行任何調整;和(ii)除非在符合TSXV政策中的適用持續上市要求的情況下,否則AVI不得行使其其他轉換權。
About Kovo HealthTech Corporation
Kovo HealthTech Corporation簡介
Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit .
Kovo HealthTech Corporatio是一家快速增長的醫療技術公司,專門提供SaaS樣式的醫療賬單管理服務,爲2250多家美國醫療機構提供軟件服務。Kovo幫助醫療服務提供商以無縫的方式處理和管理繁瑣的患者護理登記、服務、賬單和支付。目前,通過其客戶,Kovo每年爲超過350萬患者處理超過2.5億加元(2億美元)的年度賬單交易。通過提供有效的賬單實踐,Kovo幫助醫療從業者得到報酬,以便他們可以專注於提供優質的醫療保健服務。有關Kovo的更多信息以及Kovo新聞的最新動態,請訪問 。
For more information:
Peter Bak, Board Chair
investors@kovo.co
1-866-558-6777
欲了解更多信息:
Kovo董事長
investors@kovo.co
1-866-558-6777
Forward Looking Information
前瞻性信息
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Corporation's settlement of certain debt obligations owed to entities controlled by a current directors of the Corporation, the future financial condition of the Corporation and its prospects, including any proposed debt restructuring transaction, including the Debt Conversion Transaction and the Loan Agreement Amendments. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
本新聞發佈含有股份法適用範圍內的前瞻性聲明及前瞻性信息。這些聲明和信息是關於未來事件或未來表現的。除了歷史事實陳述的聲明之外,所有陳述都可能是前瞻性聲明或信息。更爲具體地且不受限制地,本新聞發佈包含有關公司結算欠某現任董事所控制公司的某些債務,公司未來財政狀況及其前景,包括任何擬議的債務重組業務的前瞻性聲明和信息,包括債務轉換交易和貸款協議修正。前瞻性聲明和信息基於公司管理層作出的某些關鍵預期和假設。儘管公司管理層相信前瞻性聲明和信息基於合理的預期和假設,但不應過度依賴前瞻性聲明和信息,因爲無法保證它們會被證明是正確的。
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Corporation's ability to continue operations without adequate capital, the Corporation's ability to raise further capital, the Corporation's ability to meet the terms of its current debt obligations and to repay its indebtedness with or without the Debt Conversion Transaction and the Loan Agreement Amendments, the likelihood of the Corporation satisfying its ongoing obligations under the proposed Debt Conversion Transaction and Loan Agreement Amendments, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties, and the likelihood of any debt restructuring transaction being consummated, and the Corporation not defaulting in the future. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
提供前瞻性陳述和信息是爲了提供有關公司管理層有關未來的當前預期和計劃的信息。讀者應注意,依賴此類陳述和信息可能不適用於其他目的,例如做出投資決策。由於前瞻性陳述和信息涉及未來事件和條件,因其本質而言,它們涉及固有的風險和不確定性。由於多種因素和風險,實際結果可能會與目前預期有所不同。這些因素和風險包括但不限於,公司無法在沒有充足資本的情況下繼續運營,公司無法籌集進一步資本,公司無法履行其當前債務義務並在有或無債務轉換交易及貸款協議修正的情況下償還其負債,公司滿足擬議債務轉換交易和貸款協議修正的持續義務的可能性,公司成功高效地開發新機會的能力,未能確定未來交易交易對手,債務重組交易可能達成的可能性,以及公司未來不違約的可能性。因此,讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。讀者應注意,上述因素列表並非詳盡無遺。本新聞稿中包含的前瞻性陳述和信息是截至本日作出的,恕不承諾公開更新或修訂任何前瞻性陳述或信息,除非適用的證券法律要求如此。本新聞稿中包含的前瞻性陳述或信息明確受到此警示性聲明的限制。